The Impact of Atrial Fibrillation on the Cost of Stroke: The Berlin Acute Stroke Study  by Brüggenjürgen, Bernd et al.
Volume 10 • Number 2 • 2007
V A L U E  I N  H E A L T H
© 2007, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/07/137 137–143 137
10.1111/j.1524-4733.2006.00160.x
Blackwell Publishing IncMalden, USAVHEValue in Health1098-30152006 Blackwell Publishing2007102137143Original ArticleThe Impact of Atrial Fibrillation on the Cost of StrokeBrüggenjürgen et al.
Address correspondence to: Bernd Brüggenjürgen, Institute
for Social Medicine, Epidemiology and Health Economics,
Charité—Universitätsmedizin Berlin, 10098, Berlin, Germany.
E-mail: bernd.brueggenjuergen@charite.de
The Impact of Atrial Fibrillation on the Cost of Stroke: 
The Berlin Acute Stroke Study
Bernd Brüggenjürgen, MD, MPH,1 Karin Rossnagel, MD,1 Stephanie Roll, MSC,1 Fredrik L. Andersson, PhD,2 
Dagmar Selim, MSC,1 Jacqueline Müller-Nordhorn, MD,1 Christian H. Nolte, MD,3 Gerhard J. Jungehülsing, MD,3 
Arno Villringer, MD,3 Stefan N. Willich, MD, MPH1
1Institute for Social Medicine, Epidemiology and Health Economics, Charité—Universitätsmedizin Berlin, Germany; 2AstraZeneca R&D, Lund, 
Sweden; 3Department of Neurology, Charité—Universitätsmedizin Berlin, Germany and Competence Network Stroke
ABSTRACT
Objectives: Atrial ﬁbrillation (AF) is an important risk factor
for stroke. The primary purpose of this study was to deter-
mine the resource use for patients admitted to hospital with
acute stroke and to calculate stroke-related direct costs, strat-
ifying the results according to the presence of AF as a risk
factor.
Methods: Data from 558 consecutive patients hospitalized
with conﬁrmed acute stroke between August 2000 and July
2001 were analyzed as part of the Berlin Acute Stroke Study.
Sociodemographic variables were assessed by direct inter-
view, while hospital data were derived from patient medical
records. Patients or their carers completed a follow-up ques-
tionnaire about resource utilization and absenteeism from
work during the 12-month period after hospital admission.
Results: Out of the 367 patients with follow-up data and
ECG ﬁndings, 71 (19%) had AF. Patients with AF were gen-
erally older, more likely to be female, and had more severe
strokes compared with those without AF. Mean direct costs
per patient were signiﬁcantly higher in those with AF-related
strokes (€11,799 vs €8817 for non-AF-related strokes;
P < 0.001). After adjustment for confounding factors, direct
costs were comparable in the two groups, except for acute
hospitalization costs, which remained signiﬁcantly higher in
the group with AF (P < 0.05).
Conclusion: Medical care for stroke patients with AF is
associated with higher costs compared with those without
AF; this is explained mainly by confounding factors and
driven essentially by a signiﬁcant difference in acute hospi-
talization costs.
Keywords: atrial ﬁbrillation, burden of disease, cost analysis,
stroke.
Introduction
Stroke is a debilitating and potentially fatal disease
with a signiﬁcant long-term economic and social bur-
den. In the United States alone, for example, the
annual cost of stroke has been estimated at $53.6 bil-
lion [1]. A major share of strokes are cardioembolic,
and the presence of atrial ﬁbrillation (AF) is a strong
risk factor in this regard [2]. Indeed, this common
cardiac arrhythmia, which has an estimated age-
dependent prevalence of 1% to 9%, is responsible for
approximately 15% of all strokes [3]. Such events also
tend to be of greater severity and associated with
increased risk of poorer neurological outcomes, med-
ical complications, and death than in patients with
non-AF-related strokes [4,5]. To the best of our knowl-
edge, however, there are no studies that have examined
whether the presence of AF impacts on costs among
patients with stroke [6]. If an impact on costs is present
and it is neglected, economic evaluations will underes-
timate the cost-effectiveness of future anticoagulation
treatment resulting in a reduced risk of stroke.
Therefore, the primary aim of the present study was
to determine the short- and long-term medical resource
use for patients admitted to hospital with acute stroke
and to calculate stroke-related direct costs, stratifying
the results according to the presence of AF as a risk
factor. In addition, labor-force-related indirect costs
were assessed.
Methods
This study used data from the Berlin Acute Stroke
Study, an ongoing study of consecutive patients admit-
ted to four German hospitals for treatment of acute
stroke over a 1-year period (August 1, 2000 to July 31,
2001). Details of the study have been reported else-
where [7]. Brieﬂy, the study was conducted at four hos-
pitals in the city of Berlin (population approximately
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420,000), including two university hospitals and two
general community hospitals, all with primary respon-
sibility for the treatment of patients with acute stroke
in their geographic areas. A total of 1094 patients with
stroke symptoms were admitted to the respective emer-
gency departments. Patients were eligible for inclusion
if they were judged by a neurologist to display signs or
symptoms of an acute stroke upon emergency depart-
ment (ED) admission, during which the National In-
stitutes of Health Stroke Scale (NIHSS) score was
recorded (using the validated German version of this
questionnaire [8]). The exclusion criteria were presen-
tation after 7 days of symptom onset, discharge or
transfer to a nonparticipating hospital within
24 hours,  death  within  24 hours  of  ED  admission,
or in-hospital stroke. Thirteen non-German speaking
patients were also excluded from enrollment. A total
of 471 (mean age 72.6 ± 14.3 years) could not be
interviewed because of immediate transfer to another
hospital, lack of informed consent, or inability to par-
ticipate in the interview without any proxies around.
The study was approved by the local ethics committee.
A total of 623 patients with suspected stroke were
able to participate in the study and consented to face-
to-face interviews that were conducted between 24
and 72 hours after hospital admission. The 50-item
interview (available at http://www.mosby.com/
AnnEmergMed) captured information on type and
course of symptoms, patient’s interpretation of
symptoms, lifestyle and medical history, help-seeking
behavior, awareness about stroke and medication, and
socio-demographic factors. In-hospital management
data, including ﬁnal diagnosis, were collected by chart
reviews after the patient had been discharged. The ﬁnal
diagnosis was based on neurological assessment and
imaging. The diagnosis of stroke was determined as “a
clinical syndrome characterized by rapidly developing
clinical signs of focal or global loss of cerebral func-
tion, lasting more than 24 hours or leading to death,
with no other apparent causes other than of vascular
origin” [9], while a diagnosis of transient ischemic
attack (TIA) followed the deﬁnition of “a neurological
symptom of vascular etiology that resolved within
24 hours” [10,11]. The neurologist’s initial diagnosis
of stroke on ED admission was changed after thor-
ough investigation in 65 patients (10%), who were
subsequently excluded from the analysis. The ﬁnal
diagnoses in these patients were mainly other neuro-
logical diseases, such as epileptic seizures with history
of stroke, multiple sclerosis, neuritis vestibularis,
myasthenia gravis, and Miller–Fisher syndrome. The
study population therefore comprised 558 patients
with conﬁrmed stroke and baseline interview. This
group received a follow-up postal questionnaire
12 months after hospital admission regarding resource
utilization and absenteeism from work, which was to
be completed by the patient or carer. A reminder was
sent after 4 weeks if there was no reply; thereafter, the
patient was contacted by telephone. One hundred sev-
enty-ﬁve patients did not respond to the follow-up
form, of which 96 could not be contacted by the local
residents’ registration ofﬁce, 28 were not willing to
participate, and 51 died. Direct costs were subse-
quently calculated by multiplying medical resource
units used with cost per unit, while indirect costs (pro-
ductivity loss of the labor-force participants) were cal-
culated by multiplying days off work or days of early
retirement with the average cost factor per day
(Table 1). A subanalysis was completed by stratifying
the data according to the presence of conﬁrmed AF.
The time horizon of the study was 1 year.
Baseline variables were compared between groups
using appropriate statistical tests. Socioeconomic sta-
Table 1 Unit costs
Cost (€)
Hospitalization (cost/day)*
Acute treatment
Stroke unit/intensive care 853
General ward 250
Readmission 309
Rehabilitation
Inpatient (cost/day)† 118
Day rehabilitation (cost/day)† 60
Outpatient (cost/session)‡
Physiotherapy 13.94
Massage 9.37
Heat pack 7.85
Exercise therapy 11.30
Occupational therapy 25.28
Speech therapy 21.22
Nursing care (cost/month)§
Nursing home 1023–1432
Nursing care at home 250–857
Visits to a health-care professional (cost/visit)||
General practitioner 12.3
Neurologist 30.6
Internal medicine specialist 30.6
Psychologist/psychotherapist 40.2
Other specialist 30.6
Lost productivity (cost/day)¶
Absenteeism from work 78.13
Early retirement 78.13
Other
Medication Per item#
Aids/modiﬁcations of home Per item#
Transport (cost/trip)
Ambulance 52
Emergency medical services 212
Emergency physician 317
Taxi 14
*Statistisches Taschenbuch Gesundheit 2002, Tab 7.7, Krankenhauskosten je Pﬂegetag
nach Ländern für Deutschland (per diem hospital costs according to Länder). 2000.
†Verband deutscher Rentenversicherungsträger. From Landesversicherungsanstalt
Niederbayern-Oberpfalz [12].
‡Vergütungsliste für krankengymnastische Leistungen, Massagen und med. Bäder
(reimbursement scheme for physiotherapies, massages, and medical spa) (§ 125
Sozialgesetzbuch V). 2002.
§Pﬂegeversicherungsgesetz (nursing insurance law) § 15, 36, 37, 43 SGB XI.
||Zentralinstitut für die kassenärztliche Versorgung in der BRD. Die 50 häuﬁgsten
Diagnosen von Patienten, Kontakthäuﬁgkeit und angeforderter Leistungsbedarf in
Punkten. 2002.
¶VdR, Durchschnittliche Bruttojahresarbeitsentgelte (average yearly gross income).
From Weimar et al. [12].
#Gelbe Liste Pharmindex (German Yellow pharmacopoiea). Neu-Isenburg. 2002.
Exchange rate: €1 = $1.32 (January 2005).
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tus was measured via length of education and gainful
employment. Resources used were compared with the
chi-square test, while costs were compared with the
Mann–Whitney U-test because of non-normal distri-
bution of data. Cost data were analyzed in three ways:
unadjusted, adjusted for confounding factors, and
adjusted for confounding factors on a logarithmic
scale (to test the impact of skewed data). These adjust-
ments were completed given the importance of con-
founding factors in this patient population and were
carried out using general linear model (GLM) analysis.
All baseline sociodemographic and clinical character-
istics reported in Table 2 were initially included, tested
for interaction, and consecutively excluded based on
statistical signiﬁcance. As the severity of stroke could
also be considered a result of the presence of AF, we
performed the adjustment both including and exclud-
ing the severity variable from the NIHSS score. No
adjustment for multiple testing was performed. All sta-
tistical analyses were performed with SAS version 8.1
(SAS Institute, Inc., Cary, NC). Costs are presented in
euros (€)—exchange rate: €1 = $1.32 (January 2005).
Results
Patient Characteristics
A total of 558 patients with conﬁrmed stroke were
interviewed (mean age 66.8 years; mean NIHSS score
5.0). ECG ﬁndings were available for 531 (95%)
patients. AF was diagnosed in 116 patients (22%).
A total of 383 patients (69% of total population)
ﬁlled out the follow-up questionnaire at 12 months
after hospital admission, of whom 16 had missing
baseline ECG information. Of the remaining 367
patients, 71 (19%) had AF. Overall, patients with AF
were generally older, more likely to be female and liv-
ing alone, had more frequent comorbidity and prior
stroke, and experienced more severe strokes than those
without AF (Table 2). Patients with AF were also less
likely to be gainfully employed than non-AF patients
(2 (31%) of 71 patients and 87 (30%) of 294 patients,
respectively).
Resource Use and Costs
Resource use, stratiﬁed according to AF status and for
all patients combined, is shown in Table 3. Overall,
stroke patients with AF tended to consume more
resources than non-AF patients, including longer
lengths of hospital stay and increased use of nursing
care. Of those 65 patients with medication a total of
nine (13%) patients with AF had received anticoagu-
lation therapy before the stroke event, of which six
(8%) patients were receiving such treatment for sec-
ondary prevention.
Direct and indirect costs, stratiﬁed according to AF
status and for all patients combined, are shown in
Table 4. Overall, total direct costs were approximately
€3000 higher in patients with AF-related strokes
(P < 0.001), and this was primarily driven by signiﬁ-
cantly increased costs for acute hospital treatment and
nursing care at home. The percentage of direct-cost
components  for  AF  and  non-AF  patients  is  shown
in Figure 1. Total indirect costs were signiﬁcantly
higher for non-AF patients than for those with AF
Table 2 Baseline sociodemographic and clinical characteristics
AF
(n = 71)
Non-AF
(n = 296) P-value*
Responders with
ECG ﬁndings 
(n = 367)†
Nonresponders/
no ECG 
(n = 191) P-value‡
Mean age (± SD) 73.7 ± 9.4 63.9 ± 13.5 <0.001 65.8 ± 13.4 68.4 ± 14.0 0.04
Female (%) 52 39 0.06 42 52 0.03
Education ≥12 years (%) 18 28 0.13 26 18 0.04
Living alone (%) 44 28 0.01 31 43 <0.001
Gainfully employed (%) 3 30 <0.001 24 19 0.13
NIHSS score (%)
0–2 31 43 0.03 41 24 <0.001
3–6 38 39 39 41
≥7 31 18 20 35
Mean NIHSS score (± SD) 5.5 ± 4.6 4.1 ± 4.1 0.008 4.3 ± 4.2 6.4 ± 5.4 <0.001
Diagnosis (%)
TIA 17 33 0.03 30 18 0.02
Stroke 77 62 65 72
Hemorrhage 6 5 5 10
Comorbidity (%)§
Diabetes mellitus 49 27 0.08 23 27 0.34
Hypertension 65 51 0.05 54 51 0.59
Cardiac insufﬁciency 23 6 <0.01 20 9 <0.01
Myocardial infarction 16 7 0.03 20 9 <0.01
Hyperlipidemia 25 35 0.16 30 33 0.56
Prior stroke (%)§ 30 17 0.02 20 22 0.43
*Comparison of AF and non-AF patients.
†Patients with questionnaire follow-up data (at 12 months) and ECG ﬁndings.
‡Comparison of responder and nonresponder patients.
§From patient recall.
AF, atrial ﬁbrillation; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack.
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(P < 0.001), and work absenteeism was the major cost
driver in this regard (Table 4).
Further statistical analysis of the cost data was com-
pleted, adjusting for confounding factors such as age,
sex, TIA, number of comorbidities, and with and with-
out NIHSS score (the logarithmic GLM adjustment
analysis provided no different results and is not further
reported). The GLM procedure indicated that, in addi-
Table 3 Mean (± SD) resource use of patients, stratiﬁed according atrial ﬁbrillation (AF) status and for all patients combined,
unadjusted
AF (n = 71) Non-AF (n = 296)
P-value
All patients (n = 367) 
n (%)
LOS or frequency
(median) n (%)
LOS or frequency 
(median) n (%)
LOS or frequency 
(median)
Hospitalization
Acute treatment 71 (100) 16 ± 10 days (15) 296 (100) 14 ± 8 days (11) 1.0 367 (100) 14 ± 8 days (12)
Stroke unit/intensive care 37 (52) 5 ± 4 days (3) 143 (48) 4 ± 3 days (3) 0.60 180 (49) 4 ± 3 days (3)
General ward 67 (94) 15 ± 10 days (13) 282 (95) 12 ± 8 days (11) 0.76 349 (95) 13 ± 8 days (11)
Readmission 13 (18) 26 ± 25 days (18) 51 (17) 16 ± 21 days (10) 0.86 64 (17) 18 ± 22 days (11)
Rehabilitation 
Inpatient 25 (35) 33 ± 28 days (22) 106 (36) 27 ± 17 days (20) 1.0 131 (36) 28 ± 20 days (20)
Day rehabilitation 2 (3) 40 ± 28 days (40) 9 (3) 28 ± 20 days (20) 1.0 11 (3) 30 ± 21 days (20)
Outpatient 20 (28) NA 72 (24) NA 0.54 92 (25) NA
Nursing care
Nursing home 3 (4) 281 ± 34 days (273) 4 (1) 209 ± 83 days (209) 0.14 7 (2) 240 ± 73 days (252)
Nursing care at home 16 (23) 247 ± 100 days (224) 40 (14) 198 ± 95 days (224) 0.07 56 (15) 211 ± 98 days (224)
Visits to a health-care professional
General practitioner 54 (76) 17 ± 14 visits (12) 216 (73) 13 ± 14 visits (10) 0.66 270 (74) 14 ± 14 visits (10)
Neurologist 21 (30) 4 ± 5 visits (3) 110 (37) 5 ± 5 visits (3) 0.27 131 (36) 5 ± 5 visits (3)
Internal medicine specialist 20 (28) 8 ± 11 visits (4) 68 (23) 6 ± 7 visits (4) 0.36 88 (24) 6 ± 8 visits (4)
Psychologist/psychotherapist 1 (1) 4 visits (4) 43 (15) 13 ± 13 visits (10) <0.001 44 (12) 12 ± 12 visits (10)
Other specialist 7 (10) 7 ± 9 visits (1) 28 (9) 6 ± 6 visits (4) 1.0 35 (10) 6 ± 7 visits (4)
Other
Medication 65 (92) NA 274 (93) NA 0.80 339 (92) NA
Aids/modiﬁcations of home 30 (42) NA 70 (24) NA 0.003 100 (27) NA
Transport 20 (28) NA 58 (20) NA 0.007 78 (21) NA
Lost productivity (age < 65) (n = 11) (n = 150) (n = 161)
Absenteeism from work 2 (18) 150 ± 127 days (150) 59 (39) 96 ± 88 days (60) 0.209 61 (38) 97 ± 89 days (60)
Early retirement 1 (9) 140 days (140) 19 (13) 159 ± 111 days (148) 1.0 20 (12) 158 ± 108 days (144)
LOS, length of stay; NA, not applicable.
Table 4 Mean (± SD) costs per patient (€), stratiﬁed according to atrial ﬁbrillation (AF) status and for all patients combined,
unadjusted
AF
(n = 71)
Non-AF
(n = 296) P-value
All patients
(n = 367)
Hospitalization
Acute treatment 5447 ± 3363 4423 ± 2774 0.004 4620 ± 2920
Readmission 1467 ± 4476 847 ± 3224 0.66 966 ± 3503
Rehabilitation
Inpatient/day rehabilitation* 1559 ± 2755 1313 ± 2128 0.81 1360 ± 2261
Outpatient 140 ± 419 129 ± 477 0.52 131 ± 466
Nursing care
Nursing home 438 ± 2118 114 ± 1048 0.11 177 ± 1327
Nursing care at home 683 ± 1524 357 ± 1108 0.05 419 ± 1204
Visits to a health-care professional
General practitioner 396 ± 446 291 ± 409 0.05 311 ± 418
Neurologist 37 ± 100 53 ± 121 0.18 50 ± 117
Internal medicine specialist 67 ± 207 39 ± 124 0.24 44 ± 143
Psychologist/psychotherapist 2 ± 19 74 ± 261 0.002 60 ± 236
Other specialist 21 ± 105 16 ± 75 0.94 17 ± 81
Other
Medication 829 ± 655 808 ± 879 0.29 812 ± 840
Aids/modiﬁcations of home 532 ± 2037 284 ± 1501 0.003 332 ± 1618
Transport 182 ± 366 71 ± 194 0.002 92 ± 241
Total
Total direct costs 11,799 ± 8292 8817 ± 7251 <0.001 9394 ± 7544
Lost productivity for age < 65 years (n = 11) (n = 150) (n = 161)
Absenteeism from work 2131 ± 5698 2940 ± 5650 0.25 2885 ± 5638
Early retirement 994 ± 3298 1572 ± 5123 0.73 1533 ± 5014
Total indirect costs for age < 65 years 3125 ± 6211 4513 ± 7348 0.27 4418 ± 7268
*Rehabilitation in Germany within a clinic could be both on an inpatient and on a per day basis.
Exchange rate: €1 = $1.32 (January 2005).
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tion to the latter variables, the interaction between AF
and both sex and comorbidity had an impact for some
cost variables (Table 5). Despite adjustments for vari-
ous potentially confounding factors, acute hospitaliza-
tion costs were still signiﬁcantly higher in patients with
AF than in the non-AF group (P < 0.05) (Table 5).
Discussion
The results of the present study, conducted at four Ger-
man hospitals in a large metropolitan area and with
patient- and/or carer-reported feedback, show that the
direct and indirect costs of stroke during a 12-month
period are considerable. The largest contributors to the
total direct costs were initial hospital stay (49%) and
rehabilitation (16%), while indirect costs due to loss of
productivity accounted for 18% of the total costs. Fur-
thermore, the present article shows that the burden of
stroke, with regard to resource utilization and the
resulting costs, differs according to AF status. Indeed,
patients with AF tended to experience more severe
strokes (in terms of higher NIHSS score), giving rise to
signiﬁcantly increased costs for acute hospitalization.
This signiﬁcant difference was somewhat unexpected
and may reﬂect perhaps a more intense and prolonged
level of care. This difference remained after adjust-
ments for age, gender, stroke type, prior stroke,
number of comorbidities, and stroke severity. Total
indirect costs due to productivity loss per patient for
AF-related strokes were lower than for non-AF related
strokes. This difference, however, may be somewhat of
an artifact as the non-AF patients, on average, were
about 10 years younger and with 87 of a total of 294
non-AF patients more likely to be in gainful employ-
ment compared with 2 of 71 total AF patients. Con-
sequently, the information value with regard to
indirect costs is limited.
Comparison with Other Studies
According to Weimar et al. [13], the mean hospitali-
zation cost of patients with ischemic stroke in Ger-
many is €4749, which is in line with the mean cost of
acute hospitalization in the present study (€4620).
Similar ﬁndings are apparent for comparative costs of
outpatient care (€2444) and inpatient rehabilitation
(€1633).
There is a limited amount of data on resource use
and costs in patients with AF-related strokes [6]. One
Danish study, by Jørgensen et al. [14], compared out-
comes data in stroke patients with and without AF and
showed that patients with AF-related stroke had a
20% increase in hospital stay and a lower discharge
Table 5 Direct costs (€), adjusted for confounding factors
Target Variable Interaction included AF Non-AF P-value Observations used (n)
NIHSS + AF, sex, age, 
TIA, comorbidity
Acute hospitalization 4,539 3,675 0.03 359
Total direct costs 13,095 12,552 0.56 359
Without NIHSS, only AF, gender, 
age, TIA, comorbidity
Acute hospitalization AF * comorbidity 4,687 3,445 0.02 360
Total direct costs AF * gender; 
AF * comorbidity
12,727 13,344 0.59 360
Exchange rate: €1 = $1.32 (January 2005).
NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack.
Figure 1 Percentage of direct-cost components for patients with (A) and
without (B) atrial ﬁbrillation (acute hospital data based on hospital chart
reviews; follow-up data based on patient questionnaire).
A
B
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rate to their own homes (both P < 0.001). Neverthe-
less, the inﬂuence of AF became insigniﬁcant when the
severity of stroke (as determined by the Scandinavian
Stroke Scale) was included in the analysis.
Sex was an important confounding factor in the
present analysis. This is in accordance with the ﬁnd-
ings of Ghatnekar et al. [15], who reported that stroke
costs in Sweden were generally higher in women than
in men.
Underuse of Prevention Therapy
Many of the patients with AF in the present study
would be candidates for oral anticoagulation therapy,
either because of prior stroke or in view of their risk
proﬁle and the need for primary stroke prevention.
Only 13% of patients with AF, however, had received
anticoagulation therapy before the stroke event. This is
consistent with reported underuse of oral anticoagula-
tion for stroke prophylaxis both in Germany [16] and
elsewhere [17], and reﬂects the fact that numerous bar-
riers exist to the effective and safe use of such therapy,
including the risk of bleeding and inconvenience [18].
Although we do not have information on possible rea-
sons for failure to use oral anticoagulation in the
present study population of patients with AF-related
strokes, it is reasonable to assume that some of the
events (and therefore resources and costs) in this real-
life population could therefore have been avoided with
effective anticoagulation.
Limitations of the Study
The exclusion criteria restricted the studied population
to the German-speaking population staying in the
admission hospital and surviving the initial 24 hours
after admission, as the study setting did not allow for
follow-up in other hospitals. This might have intro-
duced a bias toward higher costs as the deceased
patients consumed less resources. The present study
was based on a detailed interview with the patient
(and/or a carer) that was carried out within 72 hours
of ED admission for acute stroke. Consequently, some
selection bias was inevitable, not only because some
patients were unwilling to participate but also because
it was difﬁcult to obtain interview information in some
patients (e.g., because of severe stroke and/or aphasia).
Indeed, the inability of certain patients to participate
probably explains why nonresponders were character-
ized by more severe strokes than the interviewed pop-
ulation (see Table 2). Given that more severe strokes
tend to be more costly [19], this bias might have
resulted in an underestimation of the cost of stroke in
the present study. However, those having died during
the last 12 months might have consumed fewer
resources. Similarly, we relied on patient and/or carer
recall of resource utilization at 12 months after hospi-
talization, which may have also introduced a bias
toward under-reporting. However, the key cost drivers
were acute hospitalization and hospital readmissions
(together accounting for about 60% of total costs), the
data for which were provided empirically via patient
records. Future studies should perhaps try to map
resource use on a more frequent basis.
Discharge from hospital to a residential or nursing
facility (in view of functional impairment and depend-
ency), rather than the patient’s home, can signiﬁcantly
increase the cost of postacute stroke care. Although
such costs accounted for less than 10% of total costs in
the present analysis, this can be explained by the fact
that resource use was only captured for the ﬁrst
12 months after hospitalization for stroke. The full
picture therefore will only arise after several years of
follow-up. It is also important to consider that even if
the patient returns home, this can be associated with a
great deal of unpaid informal care and ﬁnancial bur-
den on family members [20], an aspect that was not
captured in the present study. This issue may be espe-
cially relevant to health-care systems where poststroke
rehabilitation services and institutional care are not
formally provided.
Another important consideration is that we only
studied patients who were alive after 12 months. We
have no information as to resource use for those who
died within 12 months of the stroke event (31 (7.5%)
of 415 patients and 19 (16.4%) of 116 patients) of
non-AF and AF patients, respectively, as the burden to
patients and carers because of follow-up contacts
should be reduced to a minimum. Selective survival of
non-AF patients, however, may have occurred and
biased the results.
Conclusion
Patients admitted to hospital in Germany with acute
stroke use signiﬁcant health-care resources that, in
turn, account for a considerable economic burden.
Medical care for stroke patients with AF is associated
with higher costs compared with those without AF;
this is explained mainly by confounding factors and
driven essentially by a signiﬁcant difference in acute
hospitalization costs.
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